Distinguishing DLBCL

Genomics-based subtyping could improve prognostic predictions for DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens.

Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of patients do not respond to the standard combination chemotherapy consisting of Rituxan rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

Read the full 526 word article

User Sign In